Stock Screener App

無料 - Play StoreApp Store

インストールインストール

TNGX

$23.889.74%2.12

Tango Therapeutics Inc (TNGX)

Date: O: H: L: C: Vol:

Tango Therapeutics Inc (TNGX) 最新ニュース

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data - Zacks Investment Research

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data - TradingView

Beyond Live Streaming: Tango Gives Back by Supporting Cancer Detection in Ukraine - GlobeNewswire Inc.

Tango Therapeutics, Inc. (TNGX) Options Chain - Yahoo Finance - Yahoo! Finance Canada

Tango Therapeutics Shares Slip 6% Even as Pancreatic Cancer Combo Shows 82% Response Rate - finance.biggo.com

Tango Therapeutics, Inc. Estimates – NASDAQ:TNGX - TradingView

Wedbush raises Tango Therapeutics stock price target on trial data - Investing.com

Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate - Yahoo Finance

Stifel raises Tango Therapeutics stock price target on trial data - Investing.com

Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? - Benzinga

Form 8K Tango Therapeutics Inc For: 23 October By Investing.com - Investing.com Nigeria

Tango Therapeutics stock falls despite positive cancer trial data By Investing.com - Investing.com Nigeria

Tango Therapeutics Reports 82% Response Rate in Pancreatic Cancer Trial - www.marketscreener.com

Tango Therapeutics reports pancreatic cancer trial data - Investing.com

Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities - TradingView

Tango Therapeutics Reports 82% Objective Response Rate for Vopimetostat Plus Daraxonrasib in Previously Treated Pancreatic Cancer; Plans Phase 3 Study in 2027 - Quiver Quantitative

Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? - Yahoo Finance

Tango Therapeutics to present pancreatic cancer study data - Investing.com

Tango Therapeutics to Present Updated Phase 1/2 Data for Vopimetostat Combinations in MTAP-Deleted RAS-Mutant Pancreatic and Lung Cancers at ESMO 2026 - Quiver Quantitative

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 - GlobeNewswire Inc.

Tango Therapeutics to Present Updated Vopimetostat + - GlobeNewswire

Tango Therapeutics stock initiated at outperform by William Blair - Investing.com

Tango Therapeutics stock initiated at outperform by William Blair - Investing.com Nigeria

Tango Therapeutics stock initiated at outperform by William Blair - Investing.com South Africa

Why Tango Therapeutics Shares Are Falling Today - Quiver Quantitative

JPMorgan reiterates Tango Therapeutics stock rating ahead of ESMO data - Investing.com

Form 4 Tango Therapeutics Inc For: 11 October By Investing.com - Investing.com South Africa

Form 4 Tango Therapeutics Inc For: 11 October By Investing.com - Investing.com Australia

Form 4 Tango Therapeutics Inc For: 11 October By Investing.com - Investing.com UK

Form 4 Tango Therapeutics Inc For: 5 October By Investing.com - Investing.com Canada

Tango therapeutics R&D president Adam Crystal sells $660k in shares. - Investing.com

Tango therapeutics R&D president Adam Crystal sells $660k in shares. - Investing.com Canada

Tango Therapeutics (TNGX) executive exercises options at $5.20 and sells 27,000 shares - Stock Titan

Tango Therapeutics Insider Sold Shares Worth $660,796, According to a Recent SEC Filing - Yahoo Finance

Form 4 Tango Therapeutics Inc For: 24 September By Investing.com - Investing.com Nigeria

Form 4 Tango Therapeutics Inc For: 24 September By Investing.com - Investing.com South Africa

Tango Therapeutics principal accounting officer sells $198k in stock - Investing.com

Under a trading plan, Tango Therapeutics (TNGX) officer Jessica Newcomb sold 8,200 shares in three transactions. - Stock Titan

How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% - Eastern Progress

Officer at Tango Therapeutics (NASDAQ: TNGX) to sell 15K shares - Stock Titan

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? - Yahoo Finance

Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path - Investing.com India

TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits

Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path - Investing.com Canada

Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey - Yahoo Finance

Tango Therapeutics' R&D President Adam Crystal Executes Option Exercise and Sells 27,000 Shares Under Rule 10b5-1 Plan - Kalkine Media

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Insider at Tango Therapeutics (TNGX) sells 27,000 shares in preset plan - Stock Titan

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - finance.yahoo.com

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo

TNGXに類似

ARQT$32.213.04%

ABCL$12.2510.16%

EWTX$38.010.26%

RLAY$17.833.18%

LEGN$21.592.30%